AR029160A1 - El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo - Google Patents

El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo

Info

Publication number
AR029160A1
AR029160A1 ARP000101572A ARP000101572A AR029160A1 AR 029160 A1 AR029160 A1 AR 029160A1 AR P000101572 A ARP000101572 A AR P000101572A AR P000101572 A ARP000101572 A AR P000101572A AR 029160 A1 AR029160 A1 AR 029160A1
Authority
AR
Argentina
Prior art keywords
kit
preparation
cell carcinoma
renal cell
alfa
Prior art date
Application number
ARP000101572A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR029160A1 publication Critical patent/AR029160A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El uso de interferon alfa pegilado, que es para la preparacion de un medicamento para tratar a un paciente que sufre de carcinoma de célula renal, para ser administrado a dicho paciente en una dosis terapéuticamente efectiva durante un período de tiempo suficiente como para lograr al menos una respuesta tumoral parcial; un kit y el uso del mismo.
ARP000101572A 1999-04-08 2000-04-06 El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo AR029160A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
AR029160A1 true AR029160A1 (es) 2003-06-18

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101572A AR029160A1 (es) 1999-04-08 2000-04-06 El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo

Country Status (24)

Country Link
EP (2) EP1535623B1 (es)
JP (2) JP3712914B2 (es)
CN (1) CN1367702A (es)
AR (1) AR029160A1 (es)
AT (2) ATE296638T1 (es)
AU (2) AU777406B2 (es)
BR (1) BR0009644A (es)
CA (1) CA2303752A1 (es)
CO (1) CO5170412A1 (es)
CY (1) CY1108919T1 (es)
DE (2) DE60020442T2 (es)
DK (2) DK1043025T3 (es)
ES (2) ES2319777T3 (es)
HK (2) HK1032533A1 (es)
HU (1) HU230271B1 (es)
MX (1) MXPA00003401A (es)
MY (1) MY155221A (es)
NO (1) NO328983B1 (es)
NZ (1) NZ514629A (es)
PE (1) PE20010026A1 (es)
PT (2) PT1535623E (es)
TW (2) TW200526243A (es)
WO (1) WO2000061174A2 (es)
ZA (1) ZA200108169B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére

Also Published As

Publication number Publication date
TWI310314B (en) 2009-06-01
DK1535623T3 (da) 2009-04-27
HUP0200781A3 (en) 2002-09-30
ES2319777T3 (es) 2009-05-12
PT1043025E (pt) 2005-09-30
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
WO2000061174A2 (en) 2000-10-19
ATE419002T1 (de) 2009-01-15
DE60041291D1 (de) 2009-02-12
DK1043025T3 (da) 2005-07-04
CY1108919T1 (el) 2014-07-02
HUP0200781A2 (en) 2002-08-28
EP1535623A1 (en) 2005-06-01
HK1075417A1 (en) 2005-12-16
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1043025B1 (en) 2005-06-01
BR0009644A (pt) 2002-01-08
ES2239953T3 (es) 2005-10-16
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
CN1367702A (zh) 2002-09-04
DE60020442D1 (de) 2005-07-07
PT1535623E (pt) 2009-03-19
DE60020442T2 (de) 2006-05-04
AU777406B2 (en) 2004-10-14
AU2004242454B2 (en) 2007-02-15
AU2004242454A1 (en) 2005-01-20
JP2000319196A (ja) 2000-11-21
HK1032533A1 (en) 2001-07-27
NO328983B1 (no) 2010-07-05
MY155221A (en) 2015-09-30
NO20014851L (no) 2001-12-07
ZA200108169B (en) 2003-01-06
NZ514629A (en) 2004-02-27
PE20010026A1 (es) 2001-02-05
CA2303752A1 (en) 2000-10-08
ATE296638T1 (de) 2005-06-15
JP2001288110A (ja) 2001-10-16
JP3712914B2 (ja) 2005-11-02
AU4204400A (en) 2000-11-14
WO2000061174A3 (en) 2001-01-25
TW200526243A (en) 2005-08-16
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
NO20014519L (no) Apomorfin- og sildenafilpreparat
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
ES2192810T3 (es) Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis.
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE298240T1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
IL159770A0 (en) Calcium salts with cytotoxic activity
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
AR029337A1 (es) Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
CO5170404A1 (es) Terapia para melanomas
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
SE0000837D0 (sv) New use
RU2001102089A (ru) Способ лечения дисциркуляторной энцефалопатии

Legal Events

Date Code Title Description
FB Suspension of granting procedure